Connect with us

Technology

NeoImmuneTech Presents Promising Interim Results of CAR-T Combination with its NT-I7 Asset at ESMO 2024

Published

on

Adequate cell expansion and persistence remains a key challenge that limits the efficacy of chimeric antigen receptor T (CAR-T) cell therapiesNew clinical results presented at ESMO 2024 show NT-I7 treatment following CAR-T cell administration is safe and well tolerated and improves clinical outcomes through successful expansion of CAR-T cells

ROCKVILLE, Md. , Sept. 9, 2024 /PRNewswire/ — NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a global leader in T cell-based immunotherapy, will present interim results of the Phase 1b clinical trial (NIT-112) combining a CAR-T therapy with NT-I7 (efineptakin alfa) during the ‘Mini oral session 1: Haematological malignancies’ at the European Society for Medical Oncology (ESMO) in Barcelona, Spain, from September 13 to 17. These initial results present a promising approach to enhancing the potential of CAR-T therapies while maintaining a stable safety profile.

The NIT-112 clinical trial involves patients with Large B-cell Lymphoma (LBCL) who received CAR-T therapies such as Kymriah, Yescarta, or Breyanzi, followed by NT-I7 administration 21 days after CAR-T infusion. The trial aims to evaluate safety, tolerability, the recommended Phase 2 dose (RP2D), and the potential for NT-I7 to enhance CAR-T expansion, persistence and stemness.

Interim results show that at dose levels 4 and 5, which are considered mid-level doses (360, 480 µg/kg), NT-I7 demonstrated a stable safety profile. No cases of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which are known as high-risk side effects of CAR-T therapies, were observed subsequent to NT-I7 administration. Only mild, manageable side effects (Grade 1-2), such as injection site erythema and swelling were observed in 6 out of 11 patients (54.5%). Overall, a strong safety profile was observed.

NT-I7 administration resulted in significant amplification of CAR-T cells, prolonged persistence and an increase in T cell stemness, characterized by a higher frequency of T cells with a stem-cell memory (Tscm) phenotype (CD45RA+CCR7+CD95+). The overall response rate (ORR) from the interim results was 81.1% (9 out of 11 patients), with 7 achieving a complete response (CR) and 2 achieving a partial response (PR). Kymriah is known to have an ORR of 52% in LBCL patients.

Dr Luke Oh, President and Chief Executive Officer of NeoImmuneTech, Inc., said: “We are thrilled by the preliminary results of study NIT-112 showing NT-I7’s ability to amplify CAR-T cells. This successful amplification of CAR-T cells is expected to translate into improved patient outcomes. NIT plans to actively pursue technology transfer related to the combination of NT-I7 with CAR-T therapies and we look forward to accelerating our discussions with the organizations already conducting preclinical studies combining NT-I7 with our own CAR-T technologies.”

Title: Phase 1b study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Presentation Number: 806MO
Speakers: Armin Ghobadi (St. Louis, United States of America)
Lecture Time: 15:05 – 15:10 (Fri, 2024. 09. 13)
Session Name: Mini oral session 1: Hematological malignancies (ID 31)
Room: Toledo Auditorium – Hall 3

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical companydedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

 

View original content:https://www.prnewswire.com/news-releases/neoimmunetech-presents-promising-interim-results-of-car-t-combination-with-its-nt-i7-asset-at-esmo-2024-302241828.html

SOURCE The NeoImmuneTech, Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Achieve named to Az Business Magazine’s ’10 Best Places for Women to Work in Arizona’ for 2026

Published

on

By

Recognition highlights the company’s commitment to creating opportunities for women to grow and lead

SAN MATEO, Calif., July 23, 2026 /PRNewswire/ — Achieve, the leader in digital personal finance, has been named among the 2026 10 Best Places for Women to Work in Arizona by Az Business Magazine. The annual recognition highlights organizations that create supportive environments where women can thrive professionally, advance into leadership roles and build meaningful careers.

The honor reflects Achieve’s ongoing investment in workplace programs that support employee growth, flexibility, leadership development and career advancement. Women serve in leadership roles across the organization and play a critical role in shaping the company’s culture, products and long-term success.

“Creating an environment where women can grow, lead and build rewarding careers is central to who we are as a company,” said Achieve Senior Vice President of Human Resources Heather Marcom. “We’re honored to be recognized among Arizona’s top workplaces for women and remain committed to fostering a culture where employees feel supported, valued and empowered to do their best work.”

Achieve maintains a major corporate presence in the Phoenix area, where hundreds of employees contribute to the company’s mission of helping people move from struggling to thriving financially. The company supports employees through leadership development opportunities, employee resource groups, mentorship and learning programs designed to help team members reach their professional goals.

The recognition adds to a growing list of workplace honors for Achieve. Earlier this year, the company was named among the Top 3 Best Workplaces for LGBTQ+ Employees by BestCompaniesAZ and was also recognized by AZ Big Media as one of Arizona’s Most Admired Companies.

“Strong organizations are built by diverse perspectives and inclusive leadership,” said Marcom. “We’re proud of the talented women across Achieve who help drive our business forward every day and grateful for the impact they make on our employees, customers and communities.”

The 10 Best Places for Women to Work in Arizona list is determined through a public voting process conducted by AZ Big Media and published in Az Business magazine.

About Achieve

Achieve, THE digital personal finance company, helps everyday people get on, and stay on, the path to a better financial future. Achieve pairs proprietary data and analytics with personalized support to offer personal loanshome equity loans, debt relief and debt consolidation, along with financial tips and education and free mobile apps: Achieve MoLO® (Money Left Over) and Achieve GOOD™ (Get Out Of Debt). Achieve is frequently recognized for providing top-rated customer experience and satisfaction by both consumers and leading personal finance review platforms and has 2,200 dedicated teammates across the country, with hubs in Arizona, California, Florida and Texas.

Achieve refers to the global organization and may denote one or more affiliates of Achieve Company, including Achieve.com, Equal Housing Opportunity (NMLS ID #138464); Achieve Home Loans, Equal Housing Opportunity (NMLS ID #1810501); Achieve Personal Loans (NMLS ID #227977); Freedom Debt Relief (NMLS ID # 1248929); and Freedom Financial Asset Management (CRD #170229).

Contacts

Austin Kilgore
akilgore@achieve.com
214-908-5097

Elina Tarkazikis
etarkazikis@achieve.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/achieve-named-to-az-business-magazines-10-best-places-for-women-to-work-in-arizona-for-2026-302833720.html

SOURCE Achieve

Continue Reading

Technology

National Press Club Statement on the withdrawal of subpoenas targeting New York Times journalists

Published

on

By

WASHINGTON, July 23, 2026 /PRNewswire/ — National Press Club President Mark Schoeff Jr. released the following statement:

“The Justice Department’s decision to withdraw subpoenas targeting journalists at The New York Times is a welcome and necessary step to protect the public’s constitutional right to an independent press.

These subpoenas should never have been issued in the first place. Compelling journalists to reveal confidential sources sends a chilling message to those who seek to inform the public and threatens the very foundation of press freedom.

Every American should understand what is at stake when the government turns its investigative powers on journalists. It is not routine. It is an extraordinary intrusion that strikes at the heart of the First Amendment and your right to information about your government.

The greatest danger was not the subpoenas themselves, but the message they sent: That sources could be exposed, that whistleblowers should remain silent, and that the American people might know less about the actions of their own government.

A strong democracy depends on a press that can report freely, hold power to account, and inform the public without intimidation.

We urge continued vigilance to ensure that journalists can do their jobs without interference and that protections for source confidentiality are upheld consistently.”

About the National Press Club

Founded in 1908, the National Press Club is the world’s leading professional organization for journalists and a leading voice for press freedom in the U.S. and worldwide.

Contact: Beth Francesco, Executive Director of the National Press Club Journalism Institute, media@press.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/national-press-club-statement-on-the-withdrawal-of-subpoenas-targeting-new-york-times-journalists-302833722.html

SOURCE National Press Club

Continue Reading

Technology

NCC Launches NCC Connect™ to Put Credit, Fraud, and Compliance Inside the CRM Dealers Already Use

Published

on

By

A powerful new solution that embeds credit access, fraud detection, and compliance directly into the dealership’s existing CRM — removing the system-switching that slows deals and exposes dealers to risk.

AUSTIN, Texas, July 23, 2026 /PRNewswire-PRWeb/ — NCC, a leading provider of credit and compliance solutions for automotive dealerships, today announced the launch of NCC Connect™, a powerful platform that runs credit, fraud, and compliance from inside the CRM a dealership already uses — without friction or duplicate entry.

“Dealers don’t need another system to log into,” said Brian Skutta, President and CEO of NCC. “They need the tools they already have to work better together. NCC Connect puts credit, fraud detection, and compliance right where the team already works — inside the CRM they use every day.”

“Dealers don’t need another system to log into,” said Brian Skutta, President and CEO of NCC. “They need the tools they already have to work better together. NCC Connect puts credit, fraud detection, and compliance right where the team already works — inside the CRM they use every day.”

As deals grow more complex and fraud more sophisticated, dealers are juggling more disconnected systems than ever — the CRM, the credit system, the compliance tools — switching between them on every transaction. Each switch breaks momentum, invites a skipped step, and slows the path to funding. NCC Connect meets this moment with a single, seamless solution that keeps the full credit, fraud, and compliance engine right where the team already works.

Why NCC Connect Matters Right Now

Dealers lose time and margin switching between the CRM, credit, and compliance systems on every dealAuto lending fraud continues to climb, with industry fraud exposure reaching a record $10.4 billion in 2025, according to Point Predictive’s 2026 Auto Lending Fraud Trends ReportState compliance is tightening, with laws like California’s SB 766 (CARS Act) taking effect October 1, 2026Every disconnected step is another chance for an error, a delay, or a deal that stalls before funding

These pressures are forcing dealers to consolidate, and NCC Connect delivers the edge.

Product Highlights:

Inside the CRM — Soft-pull and hard credit access from all three major bureaus — Experian, TransUnion, and Equifax — without leaving the workflowFraud & Identity Built In — Identity verification and synthetic fraud detection delivered within the credit pull, flagging Red Flag conditions before the deal moves to fundingCompliance on Autopilot — FCRA and FTC controls with automatic, audit-ready documentation stored in the deal record99.99% Uptime — The industry’s highest, so the platform is there when a deal is on the desk

NCC Connect runs soft-pull pre-qualifications and hard credit pulls from any bureau or score model without leaving the CRM, while customer data stays inside the existing CRM structure. Every credit, fraud, and compliance result is captured on the deal record — giving dealers a single, audit-ready source of truth and a faster, cleaner path to funding.

NCC Connect extends the same powerful, credit-first engine behind NCC’s Complete Credit™ platform into the CRM where dealers already work. For dealers, that means more approvals, stronger fraud protection, and faster funding, without changing how the team works.

Learn more about NCC Connect at https://nccdirect.com/ncc-connect/

About NCC:

With offices in Austin, TX, Bettendorf, IA, and Las Vegas, NV, NCC has been a trusted partner in credit-driven retailing for automotive dealerships for nearly three decades. We combine a powerful credit and compliance engine with a fully integrated Desking platform to drive maximum profitability. Our focus on innovation, user-friendly products, and dependable systems — supported by a dedicated account management team — has solidified our reputation as a leader in the industry. www.nccdirect.com

Media Contact

Holly Smith, NCC, 1 8285732722, hsmith@nccdirect.com, https://nccdirect.com/

View original content:https://www.prweb.com/releases/ncc-launches-ncc-connect-to-put-credit-fraud-and-compliance-inside-the-crm-dealers-already-use-302832007.html

SOURCE NCC

Continue Reading

Trending